Abstract

FORMULATION AND CHARACTERIZATION OF CLOTRIMAZOLE ORO-RETENTIVE GUMMIES FOR THE TREATMENT OF ORAL CANDIDIASIS (ANTI-FUNGAL ACTIVITY) SS

*Iyswarya S., Sakthivel M., Mohamed Halith S., Purushothaman S., Raghavi V., Ragupathi R., Rajesh R., Rajesh Kanna R.

ABSTRACT

Chewable Gummy Tablets (CGTs), also known as a gummy confection or confectionery gel, consists of sucrose or syrup combined with a gelling agent such as gelatin. Other excipients can be added to this formulation, including coloring agent, flavor and acidulant. Nowadays, CGTs have been developed as nutraceutical products since these are easier to swallow or chew compared to other dosage forms like tablets or capsules. Therefore, they are widely used in pediatric, geriatric and patients with swallowing problems. CGTs are formulated using a gelling agent as the vehicle of this product. Several hydrocolloid substances serve as gelling agents, such as gelatin, sodium alginate and gum. The selection of a gelling agent is a pivotal part of CGTs formulation because it significantly affects the physicochemical properties of these products. Chewable tablets are a versatile dosage form offering several advantages including oral drug delivery without the need lor water, ease of swallowing, the stability advantages of solid dosage forms, and planetocentric drug delivery, they provide a convenient means of pediatric drug delivery and the delivery of nutritional products such as chewable multivitamins. As a dosage form, chewable tablets have the advantages of conventional tablets in terms of manufacturability, dosing accuracy, portability, and long-term stability. Additionally, chewable tablets facilitate swallowing as the product is initially broken low into particles in the oral cavity. This is a useful patient-centric advantage for populations such as pediatrics for whom swallowing conventional tablets is a concern. As water is not required for their administration, there is a benefit of convenience when dosing, Despite the widespread use of chewable tablets there have been few comprehensive publications about them since the work of Mendes et al. in 1989. FDA published guidance in 2018 on quality attribute considerations for chewable tablets.

Keywords: .